Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-03T02:00:31.968Z Has data issue: false hasContentIssue false
  • English
  • Français

Urinary Metabolites of some Monoamines and Clinical Effects under Reserpine and Chlorpromazine

Published online by Cambridge University Press:  29 January 2018

Riccardo Bozzi ,
Antonio Bruno  and
Antonio Allegranza
Riccardo Bozzi
Affiliation:
Psychiatric Hospital of Milan, via Ippocrate 45, Milano 10/3, Italy
Antonio Bruno
Affiliation:
Psychiatric Hospital of Milan, via Ippocrate 45, Milano 10/3, Italy
Antonio Allegranza
Affiliation:
Psychiatric Hospital of Milan, via Ippocrate 45, Milano 10/3, Italy
Get access Rights & Permissions [Opens in a new window]

Extract

The purpose of this study was to investigate the relationships between the changes in the urinary excretion of the major metabolites of some monoamines and the clinical effects induced in schizophrenic subjects by treatment with reserpine or chlorpromazine.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 111 , Issue 471 , February 1965 , pp. 176 - 182
Copyright
Copyright © Royal College of Psychiatrists, 1965 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Armstrong, M., Shaw, M. F., and Wall, P. E. (1956). “The phenolic acids in human urine.” J. Biol. Chem., 218, 293–303.CrossRefGoogle Scholar
2. Armstrong, M., McMillan, A., and Shaw, N. F. (1957). “3-Methoxy-4-hydroxy-d-mandelic acid, a urinary metabolite of norepinephrine.” Biochim. Biophys. Acta, 25, 422–423.CrossRefGoogle Scholar
3. Barbeau, A., Sourkes, T. L., and Murphy, G. F. (1961). “Excretion of dopamine in diseases of basal ganglia.” Science, 133, 1706–1707.CrossRefGoogle Scholar
4. Barcroft, H., and Shaw, A. J. (1953). Sympathetic Control of Human Blood Vessels (ed. Arnold, ). London.Google Scholar
5. Bertler, A., Carlsson, A., and Rosengren, E. (1956). “Release by reserpine of catecholamines from rabbits' hearts.” Naturwiss., 43, 521.CrossRefGoogle Scholar
6. Burger, M. (1957). “Veränderungen der Adrenalin- und Noradrenalin-konzentrationen im menschlichen Blutplasma unter Reserpin.” Arch. Exper. Path. Pharmkol., 230, 489–498.Google Scholar
7. Carlsson, A. (1959). “The occurrence, distribution and physiological role of catecholamines in the nervous system.” Pharmacol. Rev., 11, 490–493.Google Scholar
8. Ehringer, H., and Hornykiewicz, D. (1960). “Verteilung von Noradrenalin und Dopamine (3-Hydroxytyramin) im Gehirndes Menschen und ihr Verhalten bei Erkränkungen des extra-pyramidalen Systems.” Klin. Wschr., 38, 1236–1239.CrossRefGoogle Scholar
9. Euler, U. S. von (1946). “A specific sympathomimetic ergone in adrenergic nerve fibres (sympathin) and its relations to adrenaline and noradrenaline.” Acta Physiol. Scand., 12, 73–77.CrossRefGoogle Scholar
10. Euler, U. S. von (1956). Noradrenaline. Chemistry, Physiology, Pharmacology and Clinical Aspects (ed. Thomas, ). Springfield, Ill. Google Scholar
11. Gaddum, J. H., Krivoy, W. A., and Laverty, G. (1958). “The action of reserpine on the excretion of adrenaline and noradrenaline.” J. Neurochem., 2, 249–253.CrossRefGoogle Scholar
12. Goodall, McC., and Kirshner, N. (1958). “Biosynthesis of epinephrine and norepinephrine by sympathetic nerves and ganglia.” Circulation, 17, 366–371.CrossRefGoogle Scholar
13. Holtz, P., Credner, K., and Kroneberg, G. (1947). “Ueber das sympathicomimetische pressorische Princip des Harns (‘Urosympathin’).” Arch. Exp. Pat. Pharmakol., 204, 228–243.CrossRefGoogle Scholar
14. Holtzbauer, M., and Vogt, M. (1956). “Depression by reserpine of the noradrenaline concentration in the hypothalamus of the cat.” J. Neurochem., 1, 8–11.CrossRefGoogle Scholar
15. Karki, N. T., and Paasonen, M. K. (1959). “Selective depletion of noradrenaline and 5-hydroxy-tryptaminc from rat brain and intestine by rauwolfia alkaloids.” Ibid., 3, 352–357.Google Scholar
16. Klee, G. D., Bertino, J., Goodman, J., and Aronson, H. (1960). “The effects of 5-hydroxy-tryptophan (a serotonin precursor) in schizophrenic patients.” J. Merit. Sci., 106, 309–316.Google Scholar
17. McDonald, R. H., and Goldberg, L. I. (1963). “Analysis of the cardiovascular effects of dopamine in the dog.” J. Pharm. Exp. Ther., 140, 60–66.Google Scholar
18. Shaw, K. N. F., McMillan, A., and Armstrong, M. D. (1957). “The metabolism of 3,4-dihydroxyphenylalanine.” J. Biol. Chem., 226, 255–256.Google Scholar
19. Sjoerdsma, A., Websbach, H., and Udenfriend, S. (1956). “A clinical, physiologic and biochemical study of patients with malignant carcinoid (argentaffinoma).” Amer. J. Med., 20, 520–532.CrossRefGoogle Scholar
20. Sjoerdsma, A., Smith, T. E., Stevenson, T. D., and Udenfriend, S. (1955). “Metabolism of 5-hydroxytryptamine (serotonin) by monoamine oxidase.” Proc. Soc. Exp. Biol. Med., 89, 36–38.CrossRefGoogle Scholar
21. Tissot, R. (1961). “Monoamines et système nervcux central.” Encéphale, 50, 205–306.Google Scholar
22. Udenfriend, S., Titus, E., and Websbach, H. (1955). “Identification of 5-hydroxy-3-indole-acetic acid in normal urine and method for its assay.” J. Biol. Chem., 216, 499–505.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.